A Phase 4 interventional study of Aripiprazole and Paliperidone in Schizophrenia, Treatment-resistant Schizophrenia and Side Effect, sponsored by Consorcio Centro de Investigación Biomédica en Red (CIBER). Not yet recruiting. Open to participants aged 15 Years to 40 Years. Per ClinicalTrials.gov, last updated 2023-09-29.
Sponsored by Consorcio Centro de Investigación Biomédica en Red (CIBER) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
SchizOMICS is a Phase IV, multicenter, dose-flexible, open-label, randomized controlled clinical trial to evaluate the efficacy and safety of aripiprazole versus paliperidone using multi-omics data in patients with a first psychotic episode. The trial will include a total of 244 patients, with two arms of treatment with paliperidone and aripiprazole (1:1).
The main objectives of the study are:
54 studies on the registry are indexed under Schizophrenia, Treatment-Resistant; 23 are open to participants now.
This study's planned enrollment of 244 is above the median of 60 across 46 interventional studies indexed under Schizophrenia, Treatment-Resistant.
Browse Schizophrenia, Treatment-Resistant studies →Consorcio Centro de Investigación Biomédica en Red (CIBER) is the lead sponsor of 18 studies on the registry; 6 are open to participants now.
Compared within Schizophrenia, Treatment-Resistant, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Schizophrenia. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Operational definition for a "first episode of psychosis" included individuals with a non-affective psychosis who have not received previous antipsychotic treatment regardless of the duration of psychosis.
Drug: Aripiprazole · Drug: Paliperidone
Oral dose range 5-30 mg/day (100 mg- 600 CPZeq). Long -acting injectables will be highly recommended in order to certify adherence.
Oral dose range 3-12 mg/day (150mg-600 CPZeq). Long -acting injectables will be highly recommended in order to certify adherence
Number of patients with a therapeutic response to aripiprazole or paliperidone
Considering response as a reduction in the Positive and Negative Symptom Scale (PANSS) \> 50%. PANSS is a test made up of 30 items that are scored from 1 (absent) to 7 (extreme).
Time frame: 3 months
Number of patients with a therapeutic response to aripiprazole or paliperidone
Considering response as Clinical Global Impression severity scale for schizophrenia (ICG-ESQ-SI) \< 4 points. ICG-ESQ-SI is a test made of 5 items that are scored from 1 (absent) to 7 (extreme).
Time frame: 3 months
Number of patients with changes in negative symptoms
Using Scale for the Assessment of Negative Symptoms (SANS), test made of 25 items that are scored from 1 (absent) to 5 (extreme).
Time frame: 12 months
Number of patients with changes in depressive symptoms
Using Calgary Depression Scale for Schizophrenia (CDSS), test made of 9 items that are scored from 1 (absent) to 4 (extreme).
Time frame: 12 months
Number of patients with changes in functionality
Using Personal and Social Performance scale (PSP), test made of 4 items that are scored from 1 (absent) to 6 (extreme).
Time frame: 12 months
Number of patients with changes in quality of life
Using EuroQoL, test made of 1 item that are scored from 0 (worst) to 100 (best).
Time frame: 12 months
Number of patients with side effects
Using UKU Side Effect Rating Scale, test made of 56 items that are scored from 0 (absent) to 3 (extreme).
Time frame: 12 months
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2023; primary completion for Jun 2025, 19 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aripiprazole · Paliperidone
Schizophrenia, Treatment-Resistant →
Consorcio Centro de Investigación Biomédica en Red (CIBER)